Vectors Research Management’s Thermo Fisher Scientific TMO Stock Holding History

Vectors Research Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Buy	4,244 +39	+0.9%	+$18.7K	0.56%	55
2026 Q1	$2.07M	Buy	4,205 +2	+0%	+$1.08K	0.6%	54
2025 Q4	$2.44M	Hold	4,203	–	–	0.74%	43
2025 Q3	$2.04M	Hold	4,203	–	–	0.64%	49
2025 Q2	$1.7M	Sell	4,203 -3,078	-42%	-$1.29M	0.58%	47
2025 Q1	$3.62M	Sell	7,281 -52	-0.7%	-$28.2K	1.27%	20
2024 Q4	$3.82M	Sell	7,333 -479	-6%	-$263K	1.3%	20
2024 Q3	$4.83M	Sell	7,812 -124	-2%	-$73.4K	1.46%	16
2024 Q2	$4.39M	Sell	7,936 -118	-1%	-$67.6K	1.35%	21
2024 Q1	$4.68M	Sell	8,054 -27,536	-77%	-$15.5M	1.32%	18
2023 Q4	$4.06M	Buy	35,590 +27,039	+316%	+$13.1M	1.14%	19
2023 Q3	$4.12M	Sell	8,551 -62	-0.7%	-$33K	1.33%	16
2023 Q2	$4.49M	Sell	8,613 -207	-2%	-$112K	1.28%	15
2023 Q1	$5.08M	Sell	8,820 -89	-1%	-$50.2K	1.31%	16
2022 Q4	$4.91M	Buy	8,909 +402	+5%	+$213K	1.27%	17
2022 Q3	$4.32M	Sell	8,507 -115	-1%	-$64.4K	1.22%	16
2022 Q2	$4.68M	Sell	8,622 -170	-2%	-$93.6K	1.19%	19
2022 Q1	$5.19M	Sell	8,792 -270	-3%	-$155K	1.14%	20
2021 Q4	$6.05M	Buy	9,062 +53	+0.6%	+$33.1K	1.28%	22
2021 Q3	$5.15M	Buy	9,009 +207	+2%	+$114K	1.21%	22
2021 Q2	$4.44M	Buy	8,802 +170	+2%	+$80.2K	1.13%	28
2021 Q1	$3.94M	Buy	8,632 +104	+1%	+$49.6K	1.09%	26
2020 Q4	$3.97M	Buy	8,528 +140	+2%	+$65.6K	1.22%	22
2020 Q3	$3.72M	Sell	8,388 -69	-0.8%	-$28.5K	1.36%	20
2020 Q2	$3.06M	Buy	8,457 +22	+0.3%	+$7.37K	1.21%	22
2020 Q1	$2.39M	Buy	8,435 +3,172	+60%	+$1M	1.14%	23
2019 Q4	$1.71M	Buy	5,263 +1,118	+27%	+$339K	0.69%	36
2019 Q3	$1.21M	Hold	4,145	–	–	0.59%	36
2019 Q2	$1.22M	Hold	4,145	–	–	0.66%	37
2019 Q1	$1.14M	Buy	4,145 +4,000	+2,759%	+$995K	0.64%	38
2018 Q4	$32K	Sell	145 -3,975	-96%	-$933K	0.02%	246
2018 Q3	$847K	Buy	+4,120	New	+$948K	0.52%	44

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vectors Research Management's TMO Position: Q2 2026 in Review

Vectors Research Management increased its Thermo Fisher Scientific (TMO) stake by 0.93% in Q2 2026, buying an estimated $18.7K and bringing the position to 4,244 shares worth $2.13M. The position accounts for 0.56% of the portfolio, ranked #55.

Vectors Research Management first reported a position in TMO in Q3 2018 and has held it in 32 quarters since. The position peaked at $6.05M in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Vectors Research Management held 4,244 shares of Thermo Fisher Scientific worth $2.13M as of Q2 2026.
Vectors Research Management bought 39 Thermo Fisher Scientific shares in Q2 2026, an estimated $18.7K.
Thermo Fisher Scientific made up 0.56% of Vectors Research Management's portfolio in Q2 2026, its #55 holding.
Vectors Research Management first reported a position in Thermo Fisher Scientific in Q3 2018 and has held it in 32 quarters since.
Vectors Research Management's Thermo Fisher Scientific position peaked at $6.05M in Q4 2021.
2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Vectors Research Management's 13F filing for Q2 2026, filed 29 Jul 2026.